封面
市場調查報告書
商品編碼
1190814

面部注射劑市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Facial Injectables Market - Growth, Trends , , and Forecasts (2023 - 2028)

出版日期: | 出版商: Mordor Intelligence | 英文 113 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

面部植入物市場預計在預測期內(2022 年至 2027 年)的複合年增長率為 12.2%。

COVID-19 的爆發減少了公共出行,推遲了非立即手術和篩查計劃以減輕醫護人員的負擔,並對治療和手術健康產生了重大影響。我正在給予 例如,根據 2020 年 5 月發表的論文“因 COVID-19 大流行而取消擇期手術:全球預測模型為手術恢復計劃提供信息”,COVID-19 導致醫院服務中斷的高峰期為 12幾週內,2020 年全球約有 2804 萬例擇期手術被取消或推遲。 此外,全球範圍內大量的 COVID-19 病例最初對整容手術率產生了短期影響。 然而,整容手術預計將在 2021 年和 2022 年在全球範圍內恢復,有望在不久的將來引領市場。

此外,審美意識的提高和整容手術數量的增加、具有成本效益的面部植入物的推出、人口老齡化等是推動市場增長的主要因素。

化妝品行業在過去十年中經歷了繁榮。 特別是,美學吸引力的激增和先進美容程序的可用性增加了非手術程序的總數,例如注射抗皺劑和真皮填充劑。 這一趨勢主要歸功於技術優勢,例如更短的恢復時間、更低的感染風險、更少的出血和更低的總體手術成本。 例如,根據國際美容整形外科學會(ISAPS)發布的《2020 年全球調查結果》報告,2020 年共進行了 10,129,528 例整容手術。 2020 年排名靠前的非手術手術包括羥基磷灰石鈣 (222,785)、聚-L 乳酸 (121,087)、肉毒桿菌毒素和透明質酸。

此外,老年人口的持續增加也推動了市場的增長。 例如,根據世界衛生組織的數據,到 2030 年,地球上將有六分之一的人超過 60 歲。 預計 60 歲及以上的人口將從 2020 年的 10 億增長到 2050 年的 14 億。 到 2050 年,世界上 60 歲及以上的人口將達到 21 億。 從 2020 年到 2050 年,80 歲及以上的人口數量預計將增加兩倍,達到 4.26 億。 這樣,老年人中老年人美容護理的趨勢有望在不久的將來推動市場增長。

市場參與者正在採取各種策略,例如產品發布、開發、合作夥伴關係、收購和擴張,以增加他們的市場份額。 例如,2021年9月,Aesthetic Innovators推出了比傳統填充劑產品體積更小的透明質酸(HA)真皮填充劑“邁力”,以及業界首款體膠原刺激填充劑“蘭露瑪”。勾選世界。

因此,上述因素預計將在預測期內推動市場增長。 然而,可用產品的副作用限制了採用,缺乏支持整容手術的報銷政策可能會在不久的將來阻礙市場增長。

面部注射市場趨勢

透明質酸部分預計在預測期內佔有很大份額

透明質酸細分市場預計將在未來幾年主導真皮填充劑細分市場。 透明質酸部分增長的一個因素是它能夠保持皮膚水分,使其看起來更健康。 這種水分結合特性有助於強化和保留使面部皮膚豐盈的重要水分。 透明質酸具有增加水合作用、改善彈性、逆轉自由基損傷和防止紫外線損傷的顯著益處。 因此,透明質酸的這些好處可能會在預測期內推動該細分市場的增長。

根據國際美容整形外科協會 2020 年世界調查於 2021 年 12 月發布的結果,透明質酸被列為非手術美容程序的前五名。 此外,據報導,2020 年共進行了 4,053,016 次透明質酸治療。 全球執行的大量手術創造了對創新產品的需求,推動了這一領域的增長。

此外,市場參與者正在採取各種策略,例如產品發布、開發、協作、合作夥伴關係、收購和擴張,以增加他們的市場份額。 例如,2020 年 6 月,艾伯維公司(Allergan Plc)獲得美國食品藥品監督管理局(FDA)的批准,用於 21 歲及以上成人的 JUVEDERM VOLUMA XC 增強頜骨。 同樣在 2020 年 8 月,Revance 推出了 RHA(彈性透明質酸)填充劑系列。 彈性透明質酸填充劑旨在適應面部運動,是美容實踐產品系列的第一步。

因此,由於上述因素,研究部門有望在預測期內實現增長。

北美主導市場,預計在預測期內也會如此

推動北美地區市場增長的因素包括對整容手術的高度認識、整容手術的技術進步、主要市場參與者的存在、老年人口的增加以及對非侵入性整容手術的需求。例如

根據美國整形外科醫生協會 (ASPS) 的數據,由於 2020 年的 COVID-19,整形外科醫生平均停止進行擇期手術的時間為 8.1 週,即一年中的 15%,這意味著手術次數。 此外,在 2020 年的住院訂單中,微創整容手術比外科手術略有下降(16% 對 14%),這是四年來的首次下降。 這種情況對大流行早期的市場增長率產生了不利影響。 然而,由於選擇性手術的恢復和美容中心的重新開放,預計該地區的市場增長將恢復到大流行前的水平。

同樣,在加拿大,人口老齡化正在推動市場增長。 根據加拿大統計局 2021 年人口普查,65 歲及以上人口約為 7,021,430 人,其中男性 3,224,680 人,女性 3,796,750 人。 隨著這個年齡段的老年人對美容護理的興趣增加,預計對美容填料的需求將會增長。

美國大公司的進駐和新產品進入市場使我們在全球市場上具有競爭優勢。 2020年1月, Revance Therapeutics 宣布完成一項變革性的美學投資組合交易,簽署了美國食品藥品監督管理局批准的 Teoxane SA 皮膚填充劑的獨家美國分銷協議。 TEOXANE SA RHA 產品組合是首批獲得 FDA 批准的用於動態皺紋矯正的真皮填充劑之一。

因此,由於上述因素,預計該地區在預測期內將呈現快速增長。

面部植入物市場競爭分析

面部注射市場的競爭很低。 市場上的主要參與者正在製定合作和產品發布策略,以滿足未滿足的美容需求。 因此,隨著醫生可以使用新的和改進的選擇,面部植入物的市場正在擴大。 公司還專注於擴大其在新興市場的影響力並與分銷商保持牢固的關係。 市場參與者包括 AbbVie Inc. (Allergan Plc)、Ipsen SA、Medytox Inc.、Merz Pharma、Sinclair Pharma Plc。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 美容意識的提高和整形手術的增加
    • 經濟高效的面部注射簡介
    • 人口老齡化
  • 市場製約因素
    • 可用產品的副作用限制了採用
    • 缺乏支持整容手術的報銷政策
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分(基於價值的市場規模:百萬美元)

  • 按類型
    • 抗皺劑
      • 肉毒桿菌毒素
    • 真皮填充劑
      • 膠原蛋白
      • 透明質酸
      • 脂肪注射
      • 聚乳酸
      • 聚甲基丙烯酸甲酯微球 (PMMA)
      • 羥基磷灰石
      • 其他真皮填充劑(例如聚烷基□亞胺)
  • 通過使用
    • 面部線條校正
    • 唇部加固
    • 整容
    • 痤瘡疤痕治療
    • 脂肪代謝障礙的治療
    • 其他用途(下巴整形、耳垂年輕化等)
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • AbbVie Inc(Allergan Plc)
    • Anika Therapeutics Inc.
    • Ipsen SA
    • Medytox Inc.
    • Merz Pharma
    • Galderma Pharma SA
    • Sanofi SA
    • Sinclair Pharma Plc
    • Suneva Medical Inc.
    • Alphaeon Corporation(Teoxane Laboratories)
    • Bloomage Biotechnology(Laboratories Vivacy SAS)
    • SciVision Biotech Inc.

第7章 市場機會與今後動向

簡介目錄
Product Code: 64173

The Facial Injectables market is expected to register a CAGR of 12.2% during the forecast period (2022-2027).

The outbreak of COVID-19 resulted in decreased public mobility and has also impacted therapeutic and surgical health significantly, as the surgical procedures and screening programs, which were non-immediate, were postponed in order to decrease the burden on healthcare professionals. For instance, according to the article titled ''Elective surgery cancellations due to the COVID-19 pandemic: global predictive modeling to inform surgical recovery plans'' published in May 2020, based on 12 weeks of peak disruption to hospital services due to COVID-19, around 28.4 million elective surgeries worldwide were canceled or postponed in 2020. In addition, a large number of cases of COVID-19 across the globe had a short-term impact on surgical rates of cosmetic procedures in the initial outbreak phase. However, owing to the resumption of elective services and cosmetic procedures around the world in 2021 and 2022, the market is anticipated to gain traction in the near future.

Furthermore, the rising aesthetic consciousness and the number of cosmetic procedures, the introduction of cost-effective facial injectables, and the aging population are some of the major factors propelling the market's growth.

The cosmetic industry has witnessed a boom over the past decade. In particular, there has been an increase in the total number of non-surgical procedures, such as injections of wrinkle relaxers and dermal fillers, due to the surge in aesthetic appeal and availability of highly advanced aesthetic procedures. This trend is primarily due to the advantages of technology, such as low recovery time, less risk of infections, no blood loss, and the overall reduction in procedural costs. For instance, according to the International Society of Aesthetic Plastic Surgery (ISAPS) published global survey results 2020 report, 10,129,528 cosmetic surgical procedures were performed in 2020. The top non-surgical procedures in 2020 include Calcium Hydroxylapatite (222,785) and Poly-L-Lactic Acid (121,087) and others such as Botulinum toxin and hyaluronic acid.

In addition, there is a consistent rise in the geriatric population, which helps to boost the market's growth. For instance, according to the World Health Organization, by 2030, 1 out of every six people on the planet will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of people aged 60 and above will reach 2.1 billion. Between 2020 and 2050, the number of people aged 80 and above is expected to triple, reaching 426 million. Thus, the growing trend with respect to geriatric aesthetics in the older population is likely to boost the market's growth in the near future.

The market players are adopting various strategies, such as product launches, developments, collaborations, partnerships, acquisitions, and expansions, to increase market share. For instance, in September 2021, Aesthetics Innovators launched two new injectables into the aesthetics sphere MaiLi, a hyaluronic acid (HA) dermal filler that uses less product than traditional fillers; and Lanluma, an industry-first collagen-stimulating filler for the body.

Thus, the abovementioned factors are likely to drive market growth over the forecast period. However, the side effects of available products, which limit adoption, and a lack of reimbursement policies supporting cosmetic procedures may impede market growth in the near future.

Facial Injectables Market Trends

Hyaluronic Acid Segment is Expected to Hold Significant Share Over the Forecast Period

The hyaluronic acid sub-segment is anticipated to dominate the dermal fillers segment over the coming years. Some of the factors responsible for hyaluronic acid segment growth include its ability to store moisture in the skin, thus making the skin look healthier. This moisture-binding characteristic helps enhance and maintain the vital moisture responsible for the plumpness of the facial skin. Hyaluronic acid has significant benefits as it increases hydration, improves elasticity, and reverses free radical damage that protects from UV damage. Thus, such advantages of hyaluronic acid are likely to boost the segment's growth over the forecast period.

According to the International Society of Aesthetic Plastic Surgery, Global Survey 2020 results, released in December 2021, hyaluronic acid is listed among the top 5 non-surgical aesthetic procedures. It also reported that a total of 4,053,016 hyaluronic acid procedures were performed in the year 2020. Such a high number of procedures performed globally creates a need for innovative products and thus drives the growth of the segment.

Moreover, the market players are adopting various strategies, such as product launches, developments, collaborations, partnerships, acquisitions, and expansions, to increase their market share. For instance, in June 2020, AbbVie Inc. (Allergan Plc) received approval from United States Food and Drug Administration (FDA) for JUVEDERM VOLUMA XC for the augmentation of the chin region in adults over the age of 21. In addition, in August 2020, Revance launched the RHA (resilient hyaluronic acid) collection of fillers. The resilient hyaluronic acid fillers are designed to adapt to facial dynamics and represent the first step in a line of products for aesthetic practices.

Thus, owing to the abovementioned factors, the studied segment is expected to project growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

Some of the factors driving the market growth in the North American region include higher awareness about aesthetic surgical procedures; technological advancements in cosmetic procedures; the presence of key market players; the increasing geriatric population; and growing demand for non-invasive aesthetic procedures.

According to the American Society of Plastic Surgeons (ASPS), in 2020, plastic surgeons stopped performing elective surgical procedures for an average of 8.1 weeks in 2020 due to COVID-19, or 15% of the year, which indicates the decline in the total number of procedures performed. Moreover, in 2020, minimally invasive cosmetic procedures decreased slightly more than surgical procedures (16% vs. 14%) during stay-at-home orders, dropping for the first time in four years. Such instances adversely impacted the market's growth rate in the initial phase of the pandemic. However, the recommencement of elective procedures and the reopening of cosmetic centers across the region are projected to help boost the market growth rate to its pre-pandemic levels.

Likewise, in Canada, the growing geriatric population is fueling the market's growth. As per the Statistics Canada 2021 census, there were around 7,021,430 people aged 65 years or above, out of which 3,224,680 were males and 3,796,750 were females. The demand for aesthetic fillers is expected to increase due to increased attention to geriatric aesthetics among this age group.

The presence of key players in United States and the launch of new products in the market gives the country an edge in the global market. In January 2020, Revance Therapeutics reported that a transformative aesthetics portfolio transaction with an exclusive United States distribution agreement for Food and Drug Administration-approved dermal fillers from Teoxane SA was completed. TEOXANE SA RHA portfolio is one of the first FDA-approved dermal fillers for correcting dynamic wrinkles.

Thus, with the abovementioned factors, the region is expected to witness rapid growth over the forecast period.

Facial Injectables Market Competitive Analysis

The facial injectables market is moderately competitive. The key players present in the market are developing collaborations and product launch strategies to address the unmet aesthetic needs. As a result, the market for facial injectables is growing due to the availability of new and improved options for physicians. The companies also focus on expanding their presence in emerging markets and maintaining strong distributor relationships. Some market players include AbbVie Inc. (Allergan Plc), Ipsen SA, Medytox Inc., Merz Pharma, and Sinclair Pharma Plc, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Aesthetic Consciousness and Number of Cosmetic Procedures
    • 4.2.2 Introduction of Cost-effective Facial Injectable
    • 4.2.3 Ageing Population
  • 4.3 Market Restraints
    • 4.3.1 Side-effects of Available Products Limiting Adoption
    • 4.3.2 Lack of Reimbursement Policies Supporting Cosmetic Procedures
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Wrinkle Relaxers
      • 5.1.1.1 Botulinum Toxin
    • 5.1.2 Dermal Fillers
      • 5.1.2.1 Collagen
      • 5.1.2.2 Hyaluronic Acid
      • 5.1.2.3 Fat Injection
      • 5.1.2.4 Polylactic Acid
      • 5.1.2.5 Polymethyl-methacrylate Microspheres (PMMA)
      • 5.1.2.6 Calcium Hydroxylapatite
      • 5.1.2.7 Other Dermal Fillers (Polyalkylimide etc.)
  • 5.2 By Application
    • 5.2.1 Facial Line Correction
    • 5.2.2 Lip Augmentation
    • 5.2.3 Face Lift
    • 5.2.4 Acne Scar Treatment
    • 5.2.5 Lipoatrophy Treatment
    • 5.2.6 Other Applications (Chin augmentation and Earlobe Rejuvenation etc.)
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc (Allergan Plc)
    • 6.1.2 Anika Therapeutics Inc.
    • 6.1.3 Ipsen SA
    • 6.1.4 Medytox Inc.
    • 6.1.5 Merz Pharma
    • 6.1.6 Galderma Pharma SA
    • 6.1.7 Sanofi SA
    • 6.1.8 Sinclair Pharma Plc
    • 6.1.9 Suneva Medical Inc.
    • 6.1.10 Alphaeon Corporation (Teoxane Laboratories)
    • 6.1.11 Bloomage Biotechnology (Laboratories Vivacy SAS)
    • 6.1.12 SciVision Biotech Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS